Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo...

Ogkologos - 10 Ιουνίου, 2025

FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma

Ogkologos - 6 Ιουνίου, 2025

Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC

Ogkologos - 6 Ιουνίου, 2025

ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June

Ogkologos - 5 Ιουνίου, 2025

EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab

Ogkologos - 5 Ιουνίου, 2025

Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients...

Ogkologos - 4 Ιουνίου, 2025

Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and...

Ogkologos - 3 Ιουνίου, 2025

Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced...

Ogkologos - 2 Ιουνίου, 2025

FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib...

Ogkologos - 30 Μαΐου, 2025

EMA Adopts a Positive Opinion for Biosimilar Denosumab

Ogkologos - 28 Μαΐου, 2025

1...484950...440 Σελίδα 49 από 440

MOST POPULAR

Alcohol linked to more than 740,000 new cancer cases globally in...

14 Ιουλίου, 2021

Breathing for Stress Reduction

10 Μαρτίου, 2021

Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced...

4 Σεπτεμβρίου, 2025

Hormone therapy gets green light for advanced prostate cancer

14 Σεπτεμβρίου, 2021

Φόρτωση περισσοτέρων

Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo...

FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma

Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC

ESMO Gynaecological Cancers Congress 2025, Vienna, Austria, 19-21 June

EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab

Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients...

Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and...

Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced...

FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib...

EMA Adopts a Positive Opinion for Biosimilar Denosumab

MOST POPULAR

Alcohol linked to more than 740,000 new cancer cases globally in...

Breathing for Stress Reduction

Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced...

Hormone therapy gets green light for advanced prostate cancer

HOT NEWS

Woman Suffers Seizure And Dies After Making Fatal Error With Her...

FDA Approves Cabozantinib for Differentiated Thyroid Cancer

John Cena Set The Record For Most Make-A-Wish Visits And He...

NHS staff shortages: What’s needed to build a sustainable cancer workforce?

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ